Related Experiment Video
Updated: Jun 8, 2025
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Postbiotics as Antiinflammatory and Immune-Modulating Bioactive Compounds in Metabolic Dysfunction-Associated
Yusuf Yilmaz1,2
1Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Türkiye.
Abstract:
Postbiotics, defined as products or metabolic byproducts secreted by live bacteria or released after bacterial lysis, are emerging as promising therapeutic agents for metabolic dysfunction-associated steatotic liver disease (MASLD). This review explores the antiinflammatory and immunomodulatory properties of various postbiotics, including exopolysaccharides, lipoteichoic acid, short-chain fatty acids, hydrogen sulfide, polyamines, tryptophan derivatives, and polyphenol metabolites. These compounds have demonstrated potential in mitigating steatotic liver infiltration, reducing inflammation, and slowing fibrosis progression in preclinical studies. Notably, postbiotics exert their beneficial effects by modulating gut microbiota composition, enhancing intestinal barrier function, optimizing lipid metabolism, reducing hepatic inflammation and steatosis, and exhibiting hepatoprotective properties. However, translating these findings into clinical practice requires well-designed trials to validate efficacy and safety, standardize production and characterization, and explore personalized approaches and synergistic effects with other therapeutic modalities. Despite challenges, the unique biological properties of postbiotics, such as enhanced safety compared to probiotics, make them attractive candidates for developing novel nutritional interventions targeting the multifactorial pathogenesis of MASLD. Further research is needed to establish their clinical utility and potential to improve liver and systemic outcomes in this increasingly prevalent condition.
Insights
Postbiotics show promise for treating metabolic dysfunction-associated steatotic liver disease (MASLD) by reducing inflammation and improving liver health. Further research is needed to confirm their clinical effectiveness and safety.
Area of Science:
- Hepatology
- Microbiology
- Immunology
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing health concern.
- Current treatments for MASLD are limited, necessitating novel therapeutic strategies.
- Postbiotics, beneficial microbial byproducts, are emerging as potential MASLD interventions.
Purpose of the Study:
- To review the anti-inflammatory and immunomodulatory properties of various postbiotics.
- To explore the potential of postbiotics in managing MASLD.
- To discuss the challenges and future directions for clinical application of postbiotics in MASLD.
Main Methods:
- Literature review of preclinical and clinical studies on postbiotics and MASLD.
- Analysis of various postbiotic compounds including exopolysaccharides, SCFAs, and polyphenol metabolites.
- Evaluation of mechanisms of action, including gut microbiota modulation and hepatoprotective effects.
Main Results:
- Postbiotics demonstrated potential in preclinical studies to reduce hepatic steatosis, inflammation, and fibrosis.
- Key mechanisms include enhancing intestinal barrier function, optimizing lipid metabolism, and modulating immune responses.
- Postbiotics offer a potentially safer alternative to probiotics for therapeutic interventions.
Conclusions:
- Postbiotics exhibit promising therapeutic potential for MASLD due to their anti-inflammatory and hepatoprotective properties.
- Clinical translation requires rigorous trials for efficacy, safety, standardization, and personalized approaches.
- Further research is essential to establish the clinical utility of postbiotics for improving liver and systemic outcomes in MASLD.
Related Concept Videos
01:24Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...